Physician profile
Voltaire Velarde
NPI 1538243340
$248.38
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $84.90 · 2021: $9.87 · 2022: $11.71.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.31 | 2019 | |
| Novo Nordisk INC | $55.81 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $28.17 | 2020 | |
| Ironwood Pharmaceuticals, INC | $23.03 | 2020 | |
| Allergan, INC. | $16.18 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.70 | 2020 | |
| Lilly USA, LLC | $11.71 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.60 | 2019 | |
| Clarus Therapeutics INC. | $9.87 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Voltaire Velarde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.